Sanofi SA (SNY) Quote| Reuters.com
Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

40.55USD
28 Jun 2016
Change (% chg)

$1.42 (+3.63%)
Prev Close
$39.13
Open
$40.12
Day's High
$40.62
Day's Low
$40.09
Volume
6,139,813
Avg. Vol
2,090,100
52-wk High
$54.98
52-wk Low
$37.41

SNY

Chart for SNY

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $100,733.70
Shares Outstanding(Mil.): 2,573.96
Dividend: 1.66
Yield (%): 4.25

Financials

  SNY Industry Sector
P/E (TTM): 21.02 33.26 34.67
EPS (TTM): 1.86 -- --
ROI: -- 14.89 14.11
ROE: -- 15.96 15.33

BRIEF-Sanofi sounding out Medivation shareholders as it prepares to raise bid- CNBC

* Sanofi sounding out Medivation shareholders as it prepares to raise bid- CNBC (Bengaluru Newsroom: +1 646 223 8780)

9:56am EDT

BRIEF-Icagen acquires Sanofi's Oro Valley, Arizona research facility

* Icagen says will retain majority of scientists working at Tucson site in transition

Jun 27 2016

Deals of the day- Mergers and acquisitions

June 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

Jun 24 2016

Glass Lewis urges Medivation shareholders to support current board

Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.

Jun 24 2016

Glass Lewis urges Medivation shareholders to support current board

June 24 Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's board members.

Jun 24 2016

Inovio Pharma gets green signal to test Zika vaccine in human trial

Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine.

Jun 20 2016

UPDATE 1-Inovio Pharma gets green signal to test Zika vaccine in human trial

June 20 Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine.

Jun 20 2016

BRIEF-Sanofi announces expiration of Hart-Scott-Rodino waiting period for proposed acquisition of Medivation

* Sanofi announces expiration of hart-scott-rodino waiting period regarding proposed acquisition of medivation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 14 2016

CORRECTED-UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight

NEW YORK, June 13 French drugmaker Sanofi and its takeover target Medivation Inc on Monday said they had filed official materials with the U.S. Securities and Exchange Commission, as their $9.3 billion battle advances to the next phase.

Jun 13 2016

Sanofi files request to replace Medivation board

PARIS French drugmaker Sanofi said on Monday that it had filed a request with U.S. authorities to remove the board of Medivation and replace it with eight independent candidates as it seeks to acquire the cancer drug company.

Jun 13 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Finlabo SIM Spa
$10.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.